Modufolin (arfolitixorin)

DRUG2 trials

Sponsors

Isofol Medical AB

Conditions

Colorectal NeoplasmPhase I Study in Healthy Volunteers to Evaluate ECG Effect

Phase 1

Modufolin (Arfolitixorin) in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer

CompletedNCT02244632

Isofol Medical ABColorectal Neoplasm

Start: 2014-09-30End: 2020-01-30Updated: 2020-09-09

Study Evaluating ECG Effects, Safety, Tolerability and Pharmacokinetics of Single Doses of Modufolin (Arfolitixorin) in Healthy Volunteers Tetrahydrofolate in Healthy Male Volunteers

CompletedNCT03203564

Isofol Medical ABPhase I Study in Healthy Volunteers to Evaluate ECG Effect

Start: 2017-07-04End: 2017-08-25Updated: 2020-09-25

Related Papers

A phase I/II study of arfolitixorin and 5-fluorouracil in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan in metastatic colorectal cancer.

2022-09-291 citations

Folate pathway gene expression in metastatic colorectal cancer patients treated with arfolitixorin/5-FU-based chemotherapy.

Journal of Clinical Oncology2021-01-202 citations

Plasma deoxyuridine as a surrogate marker for toxicity and early clinical response in patients with metastatic colorectal cancer after 5-FU-based therapy in combination with arfolitixorin

Cancer Chemotherapy and Pharmacology2020-10-245 citations

Plasma deoxyuridine levels in metastatic colorectal cancer (mCRC) patients and clinical response after 5FU based therapy in combination with arfolitixorin.

Journal of Clinical Oncology2020-02-01

ISO-CC-005; A phase I/II study of arfolitixorin (MTHF) in combination with 5-FU, irinotecan, and oxaliplatin ± bevacizumab in patients with metastasizing colorectal cancer

Annals of Oncology2018-10-011 citations

ISO-CC-005: A phase I/II study of Modufolin (MTHF) in combination with 5-FU, irinotecan, and oxaliplatin ± bevacizumab in patients with metastasizing colorectal cancer.

Journal of Clinical Oncology2018-02-01

ISO-005; An open-label, multiple-site, dose cohort, phase I/II study in patients with stage IV colorectal cancer.

Journal of Clinical Oncology2017-02-01